Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers

Author(s): Salvatore Annunziata*, Riccardo Laudicella, Federico Caobelli, Daniele A. Pizzuto, Young Aimn Working Group.

Journal Name: Current Radiopharmaceuticals

Volume 13 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: 18F-FDG PET/CT has been suggested as an effective tool to stage patients affected by melanoma. In the latest years, new radiopharmaceuticals have been proposed and the use of hybrid PET/ceCT has emerged.

Objective: To review recent evidence on the role of PET/CT in melanoma staging as well as its potential for future developments.

Methods: A comprehensive computer literature search of PubMed/MEDLINE was carried out to find relevant published articles concerning the feasibility of PET/CT in patients with malignant melanoma.

Results: Some recent studies about potentials and limitations of 18F-FDG PET/CT in staging melanoma, new PET radiotracers beyond 18F-FDG and application of hybrid PET/ceCT have been reviewed and discussed.

Conclusion: PET/CT plays an important role in the staging workup of patients affected by melanoma. New radiopharmaceuticals and hybrid PET/ceCT could improve the potential of this diagnostic tool in this field.

Keywords: PET-CT, CT, PET, 18F-FDG, melanoma, contrast.

[1]
Krug, B.; Crott, R.; Lonneux, M.; Baurain, J.F.; Pirson, A.S.; Vander Borght, T. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology, 2008, 249(3), 836-844.
[http://dx.doi.org/10.1148/radiol.2493080240] [PMID: 19011184]
[2]
Schröer-Günther, M.A.; Wolff, R.F.; Westwood, M.E.; Scheibler, F.J.; Schürmann, C.; Baumert, B.G.; Sauerland, S.; Kleijnen, J. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst. Rev., 2012, 1, 62.
[http://dx.doi.org/10.1186/2046-4053-1-62] [PMID: 23237499]
[3]
Chandra, P.; Purandare, N.; Shah, S.; Agrawal, A.; Puri, A.; Gulia, A.; Rangarajan, V. Diagnostic Accuracy and Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Preoperative Staging of Cutaneous Malignant Melanoma: Results of a Prospective Study in Indian Population. World J. Nucl. Med., 2017, 16(4), 286-292.
[http://dx.doi.org/10.4103/1450-1147.215491] [PMID: 29033677]
[4]
Singnurkar, A.; Wang, J.; Joshua, A.M.; Langer, D.L.; Metser, U. 18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study. Clin. Nucl. Med., 2016, 41(3), 189-193.
[http://dx.doi.org/10.1097/RLU.0000000000000996] [PMID: 26447374]
[5]
Ortega-Candil, A.; Rodríguez-Rey, C.; Cano-Carrizal, R.; Cala-Zuluaga, E.; González Larriba, J.L.; Jiménez-Ballvé, A.; Fuentes-Ferrer, M.E.; Cabrera-Martín, M.N.; Pérez-Castejón, M.J.; García García-Esquinas, M.; Lapeña-Gutierrez, L.; Carreras-Delgado, J.L. Breslow thickness and (18)F-FDG PET-CT result in initial staging of cutaneous melanoma: Can a cut-off point be established? Rev. Esp. Med. Nucl. Imagen Mol., 2016, 35(2), 96-101.
[http://dx.doi.org/10.1016/j.remnie.2016.01.002] [PMID: 26597332]
[6]
Freton, A.; Chin, K.J.; Raut, R.; Tena, L.B.; Kivelä, T.; Finger, P.T. Initial PET/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients. Eur. J. Ophthalmol., 2012, 22(2), 236-243.
[http://dx.doi.org/10.5301/ejo.5000049] [PMID: 21959680]
[7]
Bikhchandani, J.; Wood, J.; Richards, A.T.; Smith, R.B. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma. Head Neck, 2014, 36(9), 1313-1316.
[PMID: 23956077]
[8]
Servois, V.; Mariani, P.; Malhaire, C.; Petras, S.; Piperno-Neumann, S.; Plancher, C.; Levy-Gabriel, C.; Lumbroso-le Rouic, L.; Desjardins, L.; Salmon, R.J. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur. J. Surg. Oncol., 2010, 36(2), 189-194.
[http://dx.doi.org/10.1016/j.ejso.2009.08.010] [PMID: 19775851]
[9]
Mayerhoefer, M.E.; Prosch, H.; Herold, C.J.; Weber, M.; Karanikas, G. Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging? Eur. Radiol., 2012, 22(11), 2451-2457.
[http://dx.doi.org/10.1007/s00330-012-2499-x] [PMID: 22653282]
[10]
Brader, P.; Kelly, K.; Gang, S.; Shah, J.P.; Wong, R.J.; Hricak, H.; Blasberg, R.G.; Fong, Y.; Gil, Z. Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET. PLoS One, 2009, 4(3)e4789
[http://dx.doi.org/10.1371/journal.pone.0004789] [PMID: 19274083]
[11]
Wei, L.; Ye, Y.; Wadas, T.J.; Lewis, J.S.; Welch, M.J.; Achilefu, S.; Anderson, C.J. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl. Med. Biol., 2009, 36(3), 277-285.
[http://dx.doi.org/10.1016/j.nucmedbio.2008.12.008] [PMID: 19324273]
[12]
Wyss, M.T.; Honer, M.; Schubiger, P.A.; Ametamey, S.M. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33(3), 311-318.
[http://dx.doi.org/10.1007/s00259-005-1951-4] [PMID: 16258762]
[13]
Denoyer, D.; Potdevin, T.; Roselt, P.; Neels, O.C.; Kirby, L.; Greguric, I.; Katsifis, A.; Dorow, D.S.; Hicks, R.J. Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J. Nucl. Med., 2011, 52(1), 115-122.
[http://dx.doi.org/10.2967/jnumed.110.078154] [PMID: 21149487]
[14]
Wang, Y.; Li, M.; Zhang, Y.; Zhang, F.; Liu, C.; Song, Y.; Zhang, Y.; Lan, X. Detection of melanoma metastases with PET-Comparison of 18F-5-FPN with 18F-FDG. Nucl. Med. Biol., 2017, 50, 33-38.
[http://dx.doi.org/10.1016/j.nucmedbio.2017.03.005] [PMID: 28433794]
[15]
Zhang, C.; Zhang, Z.; Lin, K.S.; Lau, J.; Zeisler, J.; Colpo, N.; Perrin, D.M.; Bénard, F. Melanoma Imaging Using 18F-Labeled α-Melanocyte-Stimulating Hormone Derivatives with Positron Emission Tomography. Mol. Pharm., 2018, 15(6), 2116-2122.
[http://dx.doi.org/10.1021/acs.molpharmaceut.7b01113] [PMID: 29714486]
[16]
Zhang, C.; Zhang, Z.; Lin, K.S.; Pan, J.; Dude, I.; Hundal-Jabal, N.; Colpo, N.; Bénard, F. Preclinical Melanoma Imaging with 68Ga-Labeled α-Melanocyte-Stimulating Hormone Derivatives Using PET. Theranostics, 2017, 7(4), 805-813.
[http://dx.doi.org/10.7150/thno.17117] [PMID: 28382155]
[17]
Cobben, D.C.; Jager, P.L.; Elsinga, P.H.; Maas, B.; Suurmeijer, A.J.; Hoekstra, H.J. 3′-18F-fluoro-3′-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J. Nucl. Med., 2003, 44(12), 1927-1932.
[PMID: 14660718]
[18]
Sherley, J.L.; Kelly, T.J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem., 1988, 263(17), 8350-8358.
[PMID: 3372530]
[19]
Inubushi, M.; Saga, T.; Koizumi, M.; Takagi, R.; Hasegawa, A.; Koto, M.; Wakatuki, M.; Morikawa, T.; Yoshikawa, K.; Tanimoto, K.; Fukumura, T.; Yamada, S.; Kamada, T. Predictive value of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma. Ann. Nucl. Med., 2013, 27(1), 1-10.
[http://dx.doi.org/10.1007/s12149-012-0652-x] [PMID: 22914968]
[20]
Brix, G.; Lechel, U.; Glatting, G.; Ziegler, S.I.; Münzing, W.; Müller, S.P.; Beyer, T. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J. Nucl. Med., 2005, 46(4), 608-613.
[PMID: 15809483]
[21]
Morcos, S.K.; Thomsen, H.S. Adverse reactions to iodinated contrast media. Eur. Radiol., 2001, 11(7), 1267-1275.
[http://dx.doi.org/10.1007/s003300000729] [PMID: 11471623]
[22]
Albertyn, L.E. Rationales for the use of intravenous contrast medium in computed tomography. Australas. Radiol., 1989, 33(1), 29-33.
[http://dx.doi.org/10.1111/j.1440-1673.1989.tb03231.x] [PMID: 2653296]
[23]
Dizendorf, E.; Hany, T.F.; Buck, A.; von Schulthess, G.K.; Burger, C. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J. Nucl. Med., 2003, 44(5), 732-738.
[PMID: 12732674]
[24]
Antoch, G.; Freudenberg, L.S.; Egelhof, T.; Stattaus, J.; Jentzen, W.; Debatin, J.F.; Bockisch, A. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J. Nucl. Med., 2002, 43(10), 1339-1342.
[PMID: 12368372]
[25]
Pfluger, T.; Melzer, H.I.; Schneider, V.; La Fougere, C.; Coppenrath, E.; Berking, C.; Bartenstein, P.; Weiss, M. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38(5), 822-831.
[http://dx.doi.org/10.1007/s00259-010-1702-z] [PMID: 21210112]
[26]
Schüle, S.C.; Eigentler, T.K.; Garbe, C.; la Fougère, C.; Nikolaou, K.; Pfannenberg, C. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(3), 482-488.
[http://dx.doi.org/10.1007/s00259-015-3187-2] [PMID: 26384681]
[27]
Forschner, A.; Olthof, S.C.; Gückel, B.; Martus, P.; Vach, W.; la Fougère, C.; Nikolaou, K.; Keim, U.; Eigentler, T.K.; Garbe, C.; Pfannenberg, C. Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. Eur. J. Nucl. Med. Mol. Imaging, 2017, 44(8), 1312-1318.
[http://dx.doi.org/10.1007/s00259-017-3674-8] [PMID: 28315947]
[28]
Sachpekidis, C.; Kopp-Schneider, A.; Hakim-Meibodi, L.; Dimitrakopoulou-Strauss, A.; Hassel, J.C. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Res., 2018. Epub ahead of print
[PMID: 30653029]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 1
Year: 2020
Page: [6 - 13]
Pages: 8
DOI: 10.2174/1874471012666191015094620
Price: $65

Article Metrics

PDF: 13
HTML: 4
EPUB: 1
PRC: 1